Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
Prospective, Observational, Multicenter Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation (ANIMA-R)
Novartis Pharmaceuticals
300 participants
Jul 26, 2024
OBSERVATIONAL
Conditions
Summary
ANIMA-R is an observational, prospective, non-interventional, multicenter study to assess real-world effectiveness of secukinumab in the treatment of Hidradenitis Suppurativa (HS).
Eligibility
Inclusion Criteria6
- Patients who provide written informed consent form (ICF) to participate in the study.
- Male and female.
- ≥ 18 years old.
- Diagnosis of moderate or severe HS (Hurley stage and IHS4).
- Patient who initiated treatment with secukinumab no longer than 4 weeks prior to written ICF.
- Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of study participation.
Exclusion Criteria8
- Any medical or psychological condition that may prevent the study participation, based on practitioners' decision-making.
- Participation in an ongoing clinical trial.
- Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex).
- Clinically significant infection exacerbation, including active tuberculosis.
- Patients with active inflammatory bowel disease (IBD).
- Age <18 years.
- Pregnancy and breastfeeding.
- Patients who received any vaccine within 4 weeks prior to secukinumab initiation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
Locations(20)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06517732